Evidence map›Paper›PMID 36220997›Full record

ArticleBreast cancer research and treatment2022

Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors.

Rachel A Freedman, Naomi Y Ko, Ruth I Lederman, Haley Gagnon, Tsion Fikre, Daniel A Gundersen, Anna C Revette, Ashley Odai-Afotey, Olga Kantor, Dawn L Hershman and 2 more

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Providing information to prepare breast cancer patients for their surgical consultation: barriers and recommendations (an analysis from Alliance A231701CD).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rachel A FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. rafreedman@partners.org.ORCID http://orcid.org/0000-0003-0460-674X
Naomi Y KoSection of Hematology and Medical Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Ruth I LedermanSurvey and Qualitative Methods Core, Dana-Farber Cancer Institute, Boston, MA, USA.
Haley GagnonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tsion FikreSection of Hematology and Medical Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Daniel A GundersenSurvey and Qualitative Methods Core, Dana-Farber Cancer Institute, Boston, MA, USA.
Anna C RevetteSurvey and Qualitative Methods Core, Dana-Farber Cancer Institute, Boston, MA, USA.
Ashley Odai-AfoteyDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Olga KantorBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Dawn L HershmanDepartment of Medicine and Epidemiology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Katherine D CrewDepartment of Medicine and Epidemiology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Nancy L KeatingDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
American Cancer Society MRSG-14-240-01-CPPBNCI NIH HHS P30 CA013696Susan G. Komen CCRCR18552788
6 · The paper itself

Abstract

purposeThe degree to which breast cancer survivors know about their tumors and understand treatment rationales is not well understood. We sought to identify information gaps within a diverse sample and explore whether knowledge about breast cancer and treatment may impact care.

methodsWe conducted a one-time, interviewer-administered survey of women who were diagnosed with breast cancer during 2013-2017 and received care at one of three centers in Boston, MA, and New York, NY. We examined knowledge of breast cancer and treatment rationales, information preferences, and treatment receipt.

resultsDuring 2018-2020, we interviewed 313 women (American Association for Public Opinion Research Cooperation Rates 58.4-76.5% across centers) who were 56.9% White, 23.6% Black, 14.1% Hispanic, and 5.4% other. Among the 296 included in analyses, we observed high variability in knowledge of breast cancer and treatment rationales, with a substantial number demonstrating limited knowledge despite feeling highly informed; > 25% actively avoided information. Black and Hispanic (vs. White) women consistently knew less about their cancers. Lack of understanding of treatment rationales for chemotherapy, radiation, and hormonal therapy was common but not consistently different by race and ethnicity. Understanding treatment rationale (but not cancer knowledge) was associated with treatment initiation, but small sample sizes limited in-depth examination.

conclusionsOur study highlights the need for enhanced informational support for breast cancer survivors, who are challenged with complex information during the decision-making process and beyond. More research is needed to understand how to further educate and empower diverse populations of patients with breast cancer.

Indexed as

Breast NeoplasmsCancer SurvivorsBlack PeopleFemaleHispanic or LatinoHumansSurvivorsBreast cancer survivorsDecision makingDisparitiesKnowledgeSurveyTreatment rationales

Identifiers

PMID36220997
PMCPMC9552717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.